Vincerx Pharma, Inc. (VINC)
NASDAQ: VINC · Real-Time Price · USD
1.500
-0.060 (-3.85%)
At close: Jan 30, 2025, 4:00 PM
1.490
-0.010 (-0.67%)
After-hours: Jan 30, 2025, 5:53 PM EST
Vincerx Pharma Employees
Vincerx Pharma had 42 employees as of December 31, 2023. The number of employees increased by 1 or 2.44% compared to the previous year.
Employees
42
Change (1Y)
1
Growth (1Y)
2.44%
Revenue / Employee
n/a
Profits / Employee
-$643,571
Market Cap
2.52M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 42 | 1 | 2.44% |
| Dec 31, 2022 | 41 | -15 | -26.79% |
| Dec 31, 2021 | 56 | 28 | 100.00% |
| Dec 31, 2020 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
VINC News
- 7 days ago - Vincerx Pharma, Inc. Announces Reverse Stock Split - GlobeNewsWire
- 24 days ago - VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC - Business Wire
- 4 weeks ago - Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - GlobeNewsWire
- 2 months ago - Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 - GlobeNewsWire
- 4 months ago - Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates - Benzinga
- 4 months ago - Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates - GlobeNewsWire
- 6 months ago - Vincerx Pharma Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 9 months ago - Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire